ERK1/2 Inhibitor Ulixertinib in Pancancer Patients with <i>BRAF</i> Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L

Vivek Subbiah, Fengmin Zhao, Ragini R. Kudchadkar, Ryan J. Sullivan, Helen X. Chen, Robert J. Gray, Victoria Wang, Lisa M. McShane, Larry V. Rubinstein, David Patton, P. Mickey Williams, Stanley R. Hamilton, Tilak K. Sundaresan, Barbara A. Conley, James V. Tricoli, Carlos L. Arteaga, John J. Wright, Lyndsay N. Harris, Peter J. O’Dwyer, Alice P. Chen, Keith T. Flaherty

Open source

DOI: 10.1158/1078-0432.ccr-24-0951
Published: 2026-09-10
Container: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-24-0951,
  title = {ERK1/2 Inhibitor Ulixertinib in Pancancer Patients with
                    <i>BRAF</i>
                    Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L},
  author = {Vivek Subbiah and Fengmin Zhao and Ragini R. Kudchadkar and Ryan J. Sullivan and Helen X. Chen and Robert J. Gray and Victoria Wang and Lisa M. McShane and Larry V. Rubinstein and David Patton and P. Mickey Williams and Stanley R. Hamilton and Tilak K. Sundaresan and Barbara A. Conley and James V. Tricoli and Carlos L. Arteaga and John J. Wright and Lyndsay N. Harris and Peter J. O’Dwyer and Alice P. Chen and Keith T. Flaherty},
  year = {2026},
  journal = {Clinical Cancer Research},
  doi = {10.1158/1078-0432.ccr-24-0951},
  url = {https://doi.org/10.1158/1078-0432.ccr-24-0951}
}

RIS

TY  - JOUR
TI  - ERK1/2 Inhibitor Ulixertinib in Pancancer Patients with
                    <i>BRAF</i>
                    Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L
AU  - Vivek Subbiah
AU  - Fengmin Zhao
AU  - Ragini R. Kudchadkar
AU  - Ryan J. Sullivan
AU  - Helen X. Chen
AU  - Robert J. Gray
AU  - Victoria Wang
AU  - Lisa M. McShane
AU  - Larry V. Rubinstein
AU  - David Patton
AU  - P. Mickey Williams
AU  - Stanley R. Hamilton
AU  - Tilak K. Sundaresan
AU  - Barbara A. Conley
AU  - James V. Tricoli
AU  - Carlos L. Arteaga
AU  - John J. Wright
AU  - Lyndsay N. Harris
AU  - Peter J. O’Dwyer
AU  - Alice P. Chen
AU  - Keith T. Flaherty
PY  - 2026
JO  - Clinical Cancer Research
DO  - 10.1158/1078-0432.ccr-24-0951
UR  - https://doi.org/10.1158/1078-0432.ccr-24-0951
ER  -

APA

Subbiah, V., Zhao, F., Kudchadkar, R. R., Sullivan, R. J., Chen, H. X., Gray, R. J., Wang, V., McShane, L. M., Rubinstein, L. V., Patton, D., Williams, P. M., Hamilton, S. R., Sundaresan, T. K., Conley, B. A., Tricoli, J. V., Arteaga, C. L., Wright, J. J., Harris, L. N., O’Dwyer, P. J., Chen, A. P., & Flaherty, K. T. (2026). ERK1/2 Inhibitor Ulixertinib in Pancancer Patients with <i>BRAF</i> Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-24-0951

Source records

crossref · retrieved 2026-09-26T17:21:09.429Z